Antisperm antibodies in women undergoing intrauterine insemination.
Intrauterine insemination is widely used for the treatment of infertility as a result of cervical or male factors or empirically before in vitro fertilization or gamete intrafallopian transfer. This study was designed to confirm or refute the theoretical concern that intrauterine insemination may induce antisperm antibodies in such women. Serum and cervical mucus were obtained at the first, fourth, and sixth intrauterine inseminations. The serum was screened by the Immunobead test for IgG and IgA. If screening results were positive (greater than 10% binding), antisperm antibodies were titered by the microimmobilization and microagglutination tests. The Immunobead test was performed on the cervical mucus after liquefication with bromelin. Ninety-three patients were followed up prospectively. Of these, 40 completed six intrauterine insemination cycles and the remaining 53 completed four cycles. Low transient antisperm antibody levels were detected in 10.8% of the patients and would not be expected to affect the prognosis for fertility. It is concluded that intrauterine insemination does not induce significant antisperm antibody production in women.
Goldberg
J M
JM
Department of Obstetrics and Gynecology, Ohio State University, Columbus 43210.
Haering
P L
PL
Friedman
C I
CI
Dodds
W G
WG
Kim
M H
MH
D000906:Antibodies / Q000032:analysis*; D005260:Female; D006801:Humans; D007315:Insemination, Artificial; D007317:Insemination, Artificial, Homologous; D008297:Male; D013081:Sperm Motility; D013094:Spermatozoa / Q000276:immunology*
D000906:Antibodies